Fulcrum Therapeutics Prices $175 Million Public Offering of Stock and Pre-Funded Warrants

Leila Ahmed North America Legal Chronicle
Tagged:

Goodwin Procter LLP has advised Fulcrum Therapeutics. Mintz has advised the underwriters. Fulcrum Therapeutics, Inc. (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced the pricing…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Leila Ahmed

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here